Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CUL4A | Q13619 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211056 | 0.86 | KDM4E (0.40) | KDM4EHPGDHSD17B10GAAMAPT | |
| SCHEMBL8084592 | 0.82 | CUL4A (0.46) | KDM4EHPGDHSD17B10GAAMAPT | |
| SCHEMBL9814300 | 0.82 | CUL4A (0.46) | KDM4EHPGDHSD17B10GAAMAPT | |
| SCHEMBL6431583 | 0.81 | KDM4E (0.38) | KDM4EHPGDHSD17B10GAAMAPT | |
| SCHEMBL2572461 | 0.81 | TAAR1 (0.37) | KDM4EHPGDHSD17B10GAAMAPT | |
| SCHEMBL1098907 | 0.76 | TAAR1 (0.46) | KDM4EHSD17B10GAAMAPTALDH1A1 | |
| SCHEMBL1098698 | 0.75 | MAPT (0.39) | GAAMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL29739365 | 0.75 | MAPT (0.39) | GAAMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2572630 | 0.75 | PTGDR2 (0.38) | ACHEHTR4 | |
| SCHEMBL8540923 | 0.74 | HDAC1 (0.35) | KDM4EALDH1A1HTTHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| EP-0880508-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6184225-B1 | ENDOTHELIAL GROWTH FACTOR INHIBITORS, ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2001-02-06 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0880508-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | KDM4E 2469/4885HPGD 1363/4885HSD17B10 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.